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Phase II Trial of Paclitaxel and Cisplatin in Patients with
Extensive Stage Small Cell Lung Cancer: Cancer and
Leukemia Group B Trial 9430
Thomas E. Stinchcombe, MD,* Ann M. Mauer, MD,† Lydia D. Hodgson, MS,‡
James E. Herndon, II, PhD,‡ Thomas J. Lynch, MD,§ Mark R. Green, MD,
and Everett E. Vokes, MD,† and for the Cancer and Leukemia Group B
Background: Cancer and Leukemia Group B trial 9430 was a
randomized phase II trial which investigated the safety and activity
of four novel doublets in untreated extensive stage small cell lung
cancer. The results of the paclitaxel and cisplatin arm have not been
reported.
Patients and Methods: Patients received paclitaxel 230 mg/m2
followed by cisplatin 75 mg/m2 on day 1 every 21 days. All patients
received granulocyte colony stimulating factor 5 g/kg/d beginning
on day 3 of each cycle.
Results: The patient characteristics of the 34 patients assigned to
this treatment arm were: median age 61.5 years (range 41–82), male
(76%), performance status 0 (41%), 1 (32%), and 2 (26%). An
objective response was observed in 23 patients (68%; 95% confi-
dence interval (CI): 49–83%); 2 complete responses (6%) and 21
partial responses (62%). Median progression-free survival time was
5.6 months (95% CI: 4.8–7.1 month), and median overall survival
time was 7.7 months (95% CI: 7.2–12.6 months). The 1-year
survival rate observed was 29% (95% CI: 15–45%). Grade 3/4
neutropenia and thrombocytopenia was observed in 5 (15%) and 4
(12%) patients, respectively. Two patients developed febrile neutro-
penia including one patient who died of neutropenic sepsis. Grade
3/4 nonhematologic observed were: sensory neuropathy in eight
patients (24%); and hyperglycemia, malaise and nausea were all
observed in four patients (12%).
Conclusions: Cancer and Leukemia Group B will not pursue further
investigation of paclitaxel and cisplatin due to the modest activity
and the toxicity observed on this trial.
Key Words: CALGB, Paclitaxel, Chemotherapy, Lung cancer,
Small cell lung cancer.
(J Thorac Oncol. 2008;3: 1301–1307)
Lung cancer is the leading cause of cancer mortality in theUnited States, and it is estimated that in 2008 more
patients will die of lung cancer than prostate, breast, and
colorectal cancer combined.1 Of the estimated 215,000 new
cases of lung cancer, it is estimated that 13% of the cases will
be small cell histology (approximately 28,000 cases).1,2 The
majority of the patients will have extensive stage disease at
the time of diagnosis.2 In the United States, the standard
chemotherapy for extensive stage small cell lung cancer
(ES-SCLC) has been cisplatin and etoposide, which was
developed in the 1980s.3 A variety of different treatment
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strategies have been investigated to improve the survival
observed with cisplatin and etoposide. These include the use
of additional cycles of topotecan,4 maintenance chemotherapy,5,6
increasing the dose density of therapy,7 and alternating mul-
tiagent chemotherapy.8,9 Unfortunately, none of these strate-
gies has revealed an improvement in overall survival. More
recent clinical trials have investigated the combination of a
newer cytotoxic agent with cisplatin or carboplatin.10–13 Re-
cently, a phase III trial by the Japanese Clinical Oncology
Group demonstrated superior overall survival with treatment
with cisplatin and irinotecan in comparison to cisplatin and
etoposide.10 However, these results were not confirmed in a
North American phase III trial.12
At the time this trial was developed, single agent
paclitaxel had demonstrated significant activity in two coop-
erative phase II trials in untreated ES-SCLC,14,15 and activity
in patients with relapsed SCLC.16 A phase II trial performed
by the North Central Cancer Treatment Group investigated
the activity of paclitaxel 250 mg/m2 infused over 24 hours
with granulocyte colony stimulating factor (G-CSF) every 3
weeks in 43 patients with untreated ES-SCLC. This trial
revealed a response rate of 53%, and a median survival of 9.1
month.15 A phase II trial performed by Eastern Cooperative
Oncology Group investigated paclitaxel 250 mg/m2 over 24
hours in 36 patients with untreated ES-SCLC. The response
rate observed on this trial was 34% and a median survival of
9.9 months.14 Smit et al16 investigated paclitaxel 175 mg/m2
in patients with refractory disease, defined as progression
within 3 months of cytotoxic chemotherapy, and reported a
response rate of 29%. Based upon the single agent activity of
paclitaxel in ES-SCLC in phase II trials Cancer and Leuke-
mia Group B (CALGB) initiated several trials investigating
paclitaxel n ES-SCLC.17,18
CALGB trial 9430 was a randomized phase II trial to
investigate the activity of three novel chemotherapy combi-
nations: cisplatin 75 mg/m2 on day 1 and topotecan 1 mg/m2
on days 1 to 5 (arm 1), cisplatin 75 mg/m2 and paclitaxel 230
mg/m2 (arm 2) and paclitaxel 230 mg/m2 on days 1 and
topotecan 1 mg/m2 on days 1 to 5 (arm 3). The randomized
phase II trial design was chosen to assess multiple investiga-
tional combinations, and the goal of the trial was to identify
a combination for a potential phase III trial in comparison to
cisplatin and etoposide. Each treatment arm was evaluated
independently for efficacy and toxicity. Treatment arm 1
(cisplatin and topotecan) was closed after 12 patients were
enrolled due to excessive toxicity including three deaths.19
Thirteen patients were assigned to treatment arm 3 and no
complete responses were observed and excessive toxicity
including three deaths were observed, and accrual was
stopped to this treatment arm. The trial was amended and a
fourth treatment arm (paclitaxel 135 mg/m2 and topotecan 1
mg/m2 days 1 to 5) was incorporated and 32 patients were
assigned to that treatment arm.19 The doses of cisplatin and
paclitaxel were selected based on the data available from
previous phase I trials.20,21 The decision was made to publish
the three topotecan containing arms as a separate manuscript
due to the fact there was significant interest in further inves-
tigation of topotecan-based therapies and the toxicity ob-
served, and to publish the cisplatin and paclitaxel arm sepa-
rately. Although it may have been preferable to publish all
four arms in a single publication, the results of the paclitaxel
and cisplatin arm have not been previously published and are
relevant to the treatment of ES-SCLC.
PATIENTS AND METHODS
Patients were eligible for participation if they met all
the following criteria: histologically or cytologically con-
firmed diagnosis of SCLC, CALGB performance status of 0
to 2, life expectancy of 2 months, measurable or evaluable
disease, extensive stage disease, and ability to provide in-
formed consent. Extensive stage disease was defined as those
patients with extra-thoracic metastases, malignant pleural
effusions, or contralateral supraclavicular or hilar lymphade-
nopathy (precluding definitive radiation therapy). Measurable
disease was defined as a mass reproducibly measurable in two
perpendicular diameters. Evaluable disease was defined as
assessable lesions on physical examination or radiographic
studies that did not fit the category of measurable. Patients
were required to be 2 weeks since any major surgery and
patients with brain metastases were eligible if they were 3
weeks from completion of cranial irradiation. Laboratory
requirements were: absolute neutrophil count (ANC) 1800/
L; hemoglobin 10 g/dL, platelet count 100,000/L;
creatinine 1.5 times upper limit of institutional normal or
calculated creatinine clearance of 60 mL/min; bilirubin
1.5 mg/dL; and aspirate aminotransferase 2 times the
upper limit of institutional normal. Patients who were age
16, pregnant, who receive prior mediastinal or pelvic radi-
ation, systemic chemotherapy, or required ongoing cortico-
steroid administration, were excluded. Patients with a prior or
concomitant malignancy (except curatively treated carcinoma
in situ of the cervix or basal cell skin cancer) or primary
cancer that had been completely resected 5 years ago were
excluded. There was no upper limit of age for enrollment on
the trial. The following tests were required at study entry: a
complete history and physical examination, electrocardio-
gram, chest x-ray, computed tomography of the chest and
upper abdomen, and computed tomography scan or magnetic
resonance imaging of the brain, and bone scan. This protocol
was reviewed by the Institutional Review Board at the par-
ticipating institutions, and all patients were required to pro-
vide informed consent before initiating study treatment.
As part of the quality assurance program of the
CALGB, members of the Data Audit Committee visit all
participating institutions at least once every 3 years to review
source documents. The auditors verify compliance with fed-
eral regulations and protocol requirements, including those
pertaining to eligibility, treatment, adverse events, tumor
response, and outcome in a sample of protocols at each
institution. Such on-site review of medical records was per-
formed for a subgroup of 10 patients (10.4%) of the 96
patients under this study. The study chair reviewed the
eligibility for all the patients enrolled on the trial, and all the
case report forms related to patient’s treatment, toxicity, and
efficacy on the trial.
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Treatment
Patients received paclitaxel 230 mg/m2 administered
intravenously as 3-hour infusion and after completion of the
paclitaxel infusion patients received cisplatin 75 mg/m2 ad-
ministered intravenously every 21 days. All patients received
dexamethasone 10 mg, diphenhydramine 50 mg, and raniti-
dine 50 mg (or equivalent) intravenously before the paclitaxel
infusion. G-CSF support was initiated at 5 g/kg/d starting
on day 3 and continued until white blood cell count was
10,000 L after day 11. Prophylactic antiemetics, hydra-
tion, and mannitol were used at the discretion of the treating
physician. Patients who experienced stable disease or a re-
sponse after two cycles continued treatment for a maximum
of six cycles, until disease progression, unacceptable toxicity,
or patient decision to discontinue therapy. For patients who
obtained a complete response, prophylactic cranial irradiation
was allowed at the discretion of the investigator.
Dose modifications of the paclitaxel and cisplatin were
specified in the protocol for myelosuppression, nephrotoxic-
ity, neurotoxicity, and hepatic dysfunction. If grade 2 or 3
neurotoxicity developed, therapy was held until resolution to
grade 1, and then if medically appropriate resumed with a
reduction of the paclitaxel dose of 25%. Cisplatin was dis-
continued in patients who developed grade 3 neurotoxicity.
Patients were required to have adequate hematological recov-
ery (defined as an ANC 1800/L or platelet count
100,000/L) by day 22. If patients did not have adequate
hematological recovery treatment was delayed 1 week, and if
adequate recovery occurred by day 42 no dose reduction was
required for subsequent cycles. If recovery was delayed
beyond day 42 protocol therapy was discontinued. Dose
reduction was required for all patients experiencing neutro-
penic fever requiring hospitalization, a nadir platelet count of
25,000/L or neutropenia with an ANC 500/L lasting
4 days.
Assessment of Response and Toxicity
Response was assessed after every two cycles of ther-
apy. A complete response was defined as the complete dis-
appearance of tumor on clinical and radiologic examinations
without the appearance of new lesions. A partial response
was characterized as a reduction by at least 50% of the
products of longest perpendicular diameters of all measurable
lesions and no growth of new lesions lasting at least 4 weeks.
Stable disease was defined as a decrease in the sum of the
products of two perpendicular diameters of all measured
lesions by 50% or an increase by 25% after a minimum
of two cycles. Progressive disease was defined as an increase
in the product of the longest diameters of measured lesion by
25% or the appearance of new lesions. Regression of
disease was defined as the definite decrease in the size of
evaluable lesions that was agreed upon by two independent
investigators and no development of new lesions for 8
weeks.
Toxicities were assessed immediately before each treat-
ment cycle and graded according to the CALGB toxicity
criteria. Serum chemistry and liver tests were obtained before
each cycle of chemotherapy, and neurotoxicity was assessed
by history and physical examination. Patients had a complete
blood count checked at least weekly and bi-weekly, while
receiving G-CSF and before each treatment cycle.
Statistical Design
The primary objective was to evaluate the activity of
four novel combinations in patients with ES-SCLC using a
randomized phase II trial design. This study was not a
comparative trial and each treatment arm was evaluated
independently. Patients were randomized using permuted
block randomization, and no stratification factors were used.
The purpose was to determine if each combination had
sufficient activity to merit further investigation.22 A single
stage phase II design was used for each treatment regimen to
differentiate between a complete response rate of 10 and
30%. Assuming tests would be conducted with 90% power at
a 0.05 level of significance, an accrual goal of 33 patients was
set for each arm. If fewer than six patients experienced a
complete response it would be concluded that the combina-
tion had insufficient activity to merit further investigation.
Secondary objectives were to determine the overall and
progression-free survival, overall response rate (defined as
complete and partial responses combined), and toxicity.
Kaplan–Meier curves were used to describe overall and
progression-free survival. Survival was defined as time from
treatment initiation to death or last know follow-up. Progres-
sion-free survival was defined as time between initiation of
treatment until disease progression, death, or last known
follow-up (whichever occurred first). The frequency of tox-
icity was tabulated by the most severe occurrence. Patient
registration and data collection were managed by the CALGB
Statistical Center. Data quality was ensured by careful review
of the data by CALGB Statistical Center staff, and statistical
analyses were performed by CALGB statisticians.
RESULTS
Between May 1995 and March 1996, 34 patients were
assigned to receive paclitaxel and cisplatin. The majority of
the patients were men (76%), had an initial performance
status of 0 to 1 (73%), and had 5% weight loss (76%)
(Table 1). The median age was 61.5 years (range, 41–82
TABLE 1. Patient Characteristics of Cisplatin and Paclitaxel
Arm
Characteristic No. of Patients (%)
Patients enrolled 34
Median age (Range) 61.5 yr (41–82 yr)
Gender
Male 26 (76%)
Female 8 (24%)
Performance status
0 14 (41%)
1 11 (32%)
2 9 (26%)
Weight loss (%)
5 26 (76%)
5–10 4 (12%)
10 4 (12%)
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years). The patient characteristics of arm 1 (n  12), arm 3
(n  13) and arm 4 (n  32) are provided in Table 2. The
majority of the patients on the other treatment arms were
male (58%), had an initial performance status of 0 to 1 (91%),
and had 5% weight loss (60%).19
The total number of cycles administered was 156, and
the median number of cycles per patient was 5.5 (range 1–6).
The reasons for discontinuation of treatment are reported in
Table 3. The most common reasons were completion of
protocol therapy (n 16, 47%), and progressive disease (n
9, 26%). The rates of grade 3 toxicities are listed in Table
4. The primary grade 3/4 hematologic toxicities were neutro-
penia (n 5, 15%) and thrombocytopenia (n 4, 12%). One
patient experienced grade 3 febrile neutropenia without doc-
umented infection and one patient died of neutropenic sepsis
due to gram negative bactremia. The primary nonhematologic
toxicities were grade 3 sensory neuropathy (n  8, 24%),
malaise (n  4, 12%), nausea (n  4, 12%), and hypergly-
cemia (n  4, 12%). Of note six patients (18%) developed
grade 2 sensory neuropathy as well. One patient died of
unknown causes on day 11 of treatment.
All 34 patients were included in the response evalua-
tion, and the patient’s best response is characterized in Table
5. Of the 34 patients who received paclitaxel and cisplatin, 24
responses were observed yielding a response rate of 68%
(95% confidence interval (CI) 49–83%). The responses ob-
served included two complete responses (6%), and 21 partial
responses (62%). Of the 34 patients assigned to the treatment
arm 33 have died and one patient was registered on December
15, 1995 and the last known of date of contact was January
26, 2001. The median progression-free and 1-year progres-
sion-free survival were 5.6 months (95% CI, 4.8–7.1 month)
and 9% (95% CI, 2–24%), respectively (Table 4 and Figure
1). The median overall survival and 1-year survival rate were
7.7 months (95% CI, 7.2–12.6 months) and 29% (95% CI,
15–45%), respectively (Table 4 and Figure 2). The overall
response rates observed on arms 1, 3, and 4 were 42% (95%
CI, 13–76%), 54% (95% CI, 22–83%), and 69% (95% CI,
TABLE 2. Patient Characteristics of Other Treatment Arms19
No. of Patients (%)
Characteristic Arm 1 Arm 3 Arm 4
Patients 12 13 32
Median age (range) 59.5 (50, 76) 67.5 (45, 74) 60 (33, 83)
Gender
Male 10 (83%) 6 (46%) 17 (53%)
Female 2 (17%) 7 (54%) 15 (47%)
Performance status
0 2 (17%) 3 (23%) 9 (28%)
1 8 (67%) 7 (54%) 23 (72%)
2 2 (17%) 3 (23%) 0
Weight loss
5% 6 (50%) 10 (77%) 18 (56%)
5–10% 5 (42%) 2 (15%) 8 (25%)
10% 1 (8%) 1 (8%) 4 (13%)
Unknown 0 0 2 (6%)
Arm 1: cisplatin/topotecan.
Arm 3: paclitaxel (230 mg/m2)/topotecan.
Arm 4: paclitaxel (175 mg/m2)/topotecan.
TABLE 3. Reasons for Discontinuation of Study Treatment
for the Cisplatin and Paclitaxel Arm (n  34)
Reason No. of Patients (%)
Completed protocol therapy 16 (47%)
Progressive disease 9 (26%)
Patient withdrawal of consent 3 (9%)
Adverse events 2 (6%)
Death 2 (6%)
Doctor decision 2 (6%)
TABLE 4. Toxicity of Cisplatin and Paclitaxel in ES-SCLC
(n  34)a
No. of Patients (%)
Grade 3 Grade 4 Grade 5
Hematologic
Leukopenia 3 (9%) 1 (3%) —
Neutropenia 2 (6%) 3 (9%) —
Anemia 1 (3%) — —
Thrombocytopenia 3 (9%) 1 (3%) —
Febrile neutropenia 1 (3%) — 1 (3%)
Nonhematologic
Nephrotoxicity 1 (3%) 2 (6%) —
Hyperglycemia 4 (12%) — —
Sensory neuropathy 8 (24%) — —
Nausea 4 (12%) — —
Hypersensitivity — 1 (3%) —
Malaise 4 (12%) — —
Infections without neutropenia 2 (6%) — —
a Maximum toxicity grade experienced per patient.
TABLE 5. Response and Survival Rates of Cisplatin and
Paclitaxel
No. of Patients (%)
Response parameter
Complete response 2 (6%)
Partial response 21 (62%)
Regression of disease 1 (3%)
Stable disease 4 (12%)
Progression disease 3 (9%)
Nonevaluable for response 3 (9%)a
Progression-free survival
Median overall (95% CI) 5.6 mo (4.8, 7.1)
1-yr progression-free survival rate (95% CI) 9% (2, 24%)
Overall survival
Median overall (95% CI) 7.7 mo (7.2, 12.6)
1-yr overall survival rate (95% CI) 29% (15, 45%)
a Three patients were non-evaluable: Two patients due to early death, and one
patient did not undergo disease reassessment.
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48–85%), respectively.19 The other treatment were assessed
for failure-free survival, defined as time between randomiza-
tion and disease progression, death, or last known follow-up,
and overall survival (Table 6). The median failure-free sur-
vival time observed on arms 1, 3, and 4 were 4.7 (95% CI,
1.4–), 7.4 (95% CI, 1.5–) and 5.2 (95% CI, 4.5–6.9)
months, respectively. The median overall survival times for
arms 1, 3, and 4 were 5.7 (95% CI, 4.7–), 13.8 (95% CI,
1.8–) and 9.9 (95% CI, 7.6–15) months, respectively.
DISCUSSION
The results of this trial reveal that the combination of
paclitaxel and cisplatin with G-CSF support is active in
ES-SCLC, and the overall response rate (68%) observed was
comparable to other chemotherapy combinations. The com-
plete response rate (6%); however, is below the predefined
threshold for further investigation. The median survival ob-
served was 7.7 months, which is lower than the median
survival observed on previous CALGB trials in a similar
patient population.19,23 The median survival observed on the
cisplatin and paclitaxel arm is also numerically lower than the
median survival observed on recent phase III trials with
cisplatin in combination with etoposide, topotecan, or irino-
tecan.11,12
The overall response rate observed on arms 1, 3, and 4
(42, 54, and 69%, respectively) were similar to other chemo-
therapy combinations as well.19 The median survival time
observed on arms 1, 3, and 4 were 5.7, 13.8, and 9.9 months,
respectively. The excessive toxicity observed on arm 1 pre-
cluded any further investigation of that combination, and no
complete responses and excessive toxicity were observed on
arm 3, and that combination was not investigated further. The
FIGURE 1. Progression-free survival with 95% CI.
Median progression-free survival time 5.6 months,
and 1-year progression-free survival rate 9%.
FIGURE 2. Overall survival with 95% CI. Median
overall survival time 7.7 months, and 1-year over-
all survival rate 29%.
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complete response rate, failure-free survival time, median
survival time, and 1-year survival rate observed on arm 4
were similar to the results of a previous CALGB trial with
cisplatin and etoposide, and that combination was not inves-
tigated further.23
The most frequent nonhematologic toxicity was sen-
sory neuropathy; 18% of patients experienced grade 2 and
24% experienced grade 3 sensory neuropathy. The rate of
grade 3 sensory neuropathy observed on this trial is similar to
other trials in advanced non-small cell lung cancer and
breast cancer with this combination.24,25 The hematologic
toxicity was moderate with the use of prophylactic G-CSF
supportive therapy, but one patient did experience febrile
neutropenia and one patient did experience fatal neutro-
penic sepsis. The rate of toxicity observed with this com-
bination is not substantially different from currently avail-
able combination therapies.
Other CALGB trials have investigated the activity of
paclitaxel in untreated ES-SCLC. CALGB trial 39901 inves-
tigated single agent paclitaxel in patients with untreated
ES-SCLC (n  36).17 Patients received paclitaxel 150 mg/m2
over 3 hours weekly for six consecutive weeks every 8
weeks. The overall response rate observed on this trial was
33% (3% complete response and 30% partial response), and
the median progression-free and overall survival observed
were 3.7 (95% CI, 3.3–5.8) and 9.2 months (95% CI, 6.7–
14.8), respectively. CALGB trial 9732 was a phase III trial,
which investigated cisplatin/etoposide with and without pac-
litaxel (n  587).18 There was no statistically significant
difference between the standard treatment arm and the pac-
litaxel containing arm, but the toxicity was greater on the
paclitaxel containing arm. The median survival time observed
on the cisplatin and etoposide and cisplatin, etoposide, and
paclitaxel treatment arms were 9.9 months (95% CI, 9.2–
10.8) and 10.6 months (95% CI, 9.9–11.2) respectively; and
both were superior to the median survival time observed on
the current trial.
The combination of paclitaxel and carboplatin has pre-
viously been investigated in patients with untreated ES-SCLC
in two phase II trials.26,27 A phase II trial performed by
Thomas et al.26 investigated treatment with paclitaxel and
carboplatin every 3 weeks (n  50). The response rate
observed was 65% (95% CI, 51–80%) with three complete
responses and 27 partial responses. The median overall sur-
vival observed was 38 weeks. A second phase II trial per-
formed by Gridelli et al.27 investigated paclitaxel and carbo-
platin every 4 weeks (n  48). The response rate observed
was 54.2% (95% CI, 39.2–68.6%) with three complete re-
sponses and 23 partial responses. The median overall survival
observed was 9.6 months (95% CI, 7.2–14.6 months). The
overall response rates and the number of complete responses
observed on these two trials are similar to the results observed
on our trial.
In addition to these phase II trials, two phase III trials
have compared paclitaxel and carboplatin to anthracycline
containing treatments regimens.28,29 A phase III trial per-
formed by de Jong et al.28 compared treatment with cyclo-
phosphamide, doxorubicin, and etoposide every 3 weeks
versus paclitaxel and carboplatin every 3 weeks. The median
progression-free survival times observed on the paclitaxel
and carboplatin and cyclophosphamide, doxorubicin, and
etoposide treatment arms were similar (5.2 versus 4.9
months, respectively; p  0.60), and the median overall
survival times were similar as well (6.7 versus 6.8 months,
respectively). The preliminary results of a second phase III
trial which compared paclitaxel and carboplatin every 3
weeks to cyclophosphamide, doxorubicin, and vincristine
every 3 weeks are available as well.29 Patients who had
limited and extensive stage disease with a prognostic score in
the intermediate and poor range were enrolled, and the
objectives were to determine the one-year survival rate, the
objective response rate, and toxicity. There was a statistically
significant difference in survival time favor of the paclitaxel
and carboplatin (p 0.014). The 1-year survival rates and the
TABLE 6. Response and Survival Rates for Other Treatment Arms19
Arm 1 Arm 3 Arm 4
No. of patients 12 13 32
Complete response 1 (8%) 0 2 (6%)
Partial response 4 (33%) 7 (54%) 20 (63%)
Stable disease 2 (17%) 0 3 (9%)
Progressive disease 2 (17%) 2 (15%) 3 (9%)
Early death 3 (25%) 2 (15%) 2 (6%)
Nonevaluable for response 0 2 (15%) 2 (6%)
Failure-free survival
Median (95% CI) in mo 4.7 (1.4, ) 7.4 (1.5, ) 5.2 (4.5, 6.9)
1-yr failure-free survival rate 8% (1, 54%) 8% (1, 50%) 3% (0.5, 21%)
Overall survival
Median (95% CI) in mo 5.7 (4.7, ) 13.8 (1.8, ) 9.9 (7.6, 15)
1-yr overall survival rate 17% (5, 59%) 62% (40, 95%) 40% (26, 61%)
Arm 1: cisplatin/topotecan.
Arm 3: paclitaxel (230 mg/m2)/topotecan.
Arm 4: paclitaxel (175 mg/m2)/topotecan.
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median survival time for cyclophosphamide, doxorubicin,
and vincristine and paclitaxel and carboplatin were 6 and
13%, respectively, and 94 and 154 days, respectively. The
poor median survival times observed on this trial may be
related to the selection of patients with intermediate and poor
prognostic scores. The results of these trials indicate that it is
unlikely that the combination of paclitaxel and carboplatin
will provide a clinically significant improvement in survival
in comparison to currently available therapies for patients
with ES-SCLC.
In conclusion, the results of CALGB 9430 do not
support the continued investigation of paclitaxel and cisplatin
in ES-SCLC given the low complete response rate, modest
median survival, and toxicities observed.
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